RecruitingNCT05272241

Registry of Asthma Characterization and Recruitment 3 (RACR3)

Registry of Asthma Characterization and Recruitment 3 (RACR3) (CAUSE-02)


Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)

Enrollment

1,500 participants

Start Date

Apr 15, 2022

Study Type

OBSERVATIONAL

Conditions

Summary

This is a multi-center, non-interventional registry to create and maintain a database of participants to serve as a recruitment source for current and future DAIT NIAID-sponsored Childhood Asthma in Urban Settings (CAUSE) studies.


Eligibility

Inclusion Criteria4

  • Participant is either:
  • At least 18 years old, willing and able to provide informed consent at the time of enrollment
  • Under the age of 18, accompanied by a legal guardian who is willing and able to provide informed consent at the time of enrollment
  • Participant has a primary place of residence within the Office of Management and Budget (OMB)-defined Metropolitan Statistical Area (MSA)

Exclusion Criteria5

  • Participant does not speak English or Spanish and/or guardian does not speak English or Spanish
  • Participant does not have access to a phone, either personal or public, with regularity that could be used for scheduling and safety follow-up
  • Past or current medical problems or findings from physical examination or laboratory testing, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may affect the quality or interpretation of the data obtained from the study
  • Participants who are pregnant or lactating will not be excluded or discontinued from the study, but will not undergo any procedures that are prohibited during pregnancy per the Childhood Asthma in Urban Settings 02 (CAUSE-02) Registry for Asthma Characterization and Recruitment 3 (RACR3) Manual of Procedures (MOP)(e.g., allergen skin testing, spirometry) during the pregnancy.
  • Potential participants may be reassessed as outlined in the Protocol CAUSE-02 MOP.

Locations(7)

Children's Hospital Colorado: Allergy Program

Aurora, Colorado, United States

Children's National Medical Center: Inner City Asthma Consortium (ICAC) Clinical Research Site

Washington D.C., District of Columbia, United States

Ann & Robert H. Lurie Children's Hospital of Chicago: Division of Allergy and Immunology

Chicago, Illinois, United States

Boston Children's Hospital: Department of Immunology

Boston, Massachusetts, United States

Icahn School of Medicine at Mount Sinai: Division of Clinical Immunology, Immunology Institute

New York, New York, United States

Columbia University Medical Center: Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine

New York, New York, United States

Cincinnati Children's Hospital Medical Center: Asthma Center

Cincinnati, Ohio, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05272241


Related Trials